Checkpoint Inhibitor May Help Improve Outcomes in Ovarian Cancer Patients

Article

Researchers are hoping that adding a checkpoint inhibitor to the treatment armamentarium may help improve outcomes in patients with locally advanced or metastatic disease epithelial ovarian cancer.

Researchers are hoping that adding a checkpoint inhibitor to the treatment armamentarium may help improve outcomes in patients with locally advanced or metastatic disease (stage III/IV) epithelial ovarian cancer. 

A phase III study, JAVELIN Ovarian 100, is now beginning and it will evaluate the efficacy and safety of avelumab (MSB0010718C) in combination with, and/or as maintenance treatment to, platinum-based chemotherapy in patients with previously untreated epithelial ovarian cancer. JAVELIN Ovarian 100 is the first phase III study evaluating the addition of an immune checkpoint inhibitor to standard-of-care in first-line treatment for this patient population.

“In an early ongoing study, avelumab showed encouraging tumor response rates in patients with recurrent or refractory ovarian cancer,” said Alise Reicin, MD, who heads up Global Clinical Development at the biopharma business of Merck KGaA, Darmstadt, Germany, which in the US and Canada operates as EMD Serono, in a press release. “Historically, ovarian cancer presents as an advanced disease with poor survival rates. The hope is that avelumab can change the natural history of the disease and potentially take the survival rate beyond the current five year estimate.”

JAVELIN Ovarian 100 is an open-label, international, multicenter, randomized (1:1:1) trial designed to evaluate the potential superiority of two first-line therapies with avelumab and platinum-based chemotherapy versus platinum-based chemotherapy alone, as assessed by progression-free survival (PFS). The study will enroll approximately 950 patients and they will receive concurrent avelumab and chemotherapy, avelumab following chemotherapy, or chemotherapy alone.  

The investigators are hoping there will be synergistic activity in the combination of avelumab and established treatments such as platinum-based chemotherapy. Avelumab is an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody. It is theorized that by inhibiting PD-L1 interactions, this agent enables the activation of T cells and the adaptive immune system.

As of May 2016, the complete JAVELIN clinical development program for avelumab has included approximately 2,200 patients being treated across more than 15 tumor types. This agent is being evaluated in patients with mesothelioma, Merkel cell carcinoma, gastric/gastroesophageal junction cancer, urothelial carcinoma, adrenocortical carcinoma, NSCLC (non-small cell lung cancer) and renal cell carcinoma.

For this current phase III trial, eligible patients must have previously untreated, histologically confirmed stage III/IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy. The primary outcome measures include PFS and secondary outcome measures include overall survival (OS), maintenance PFS, duration of response (DR), and objective response rate (ORR).

                                                              

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content